INTRODUCTION
Apolipoprotein AI and CIII (apo AI and CIII) play an important role in the metabolism of plasma lipoproteins and lipids (Herbert et al., 1983) . The human apo AI and apo CIII genes are tightly linked and form a gene complex together with the apo AIV gene on the long arm of the chromosome 11 (Karathanasis, 1985) . A mutation of the apo AI gene is associated with low plasma HDL and premature atherosclerosis (Karathanasis et al., 1983a (Karathanasis et al., , 1983b . In addition, restriction fragment length polymorphisms related to the apo AI and apo CIII genes have been reported to be associated with coronary atherosclerosis and familial hypoalphalipoproteinemia in Caucasians (Ferns et aI., 1985; Rees et al., 1985; Sidoli et al., 1985; Ferns and Galton, 1986; Ordovas et al., 1986; Buraczynska et al., 1986; Deeb et al., 1986; Acton et al., 1986 ). An apo AI-CIII gene polymorphism associated with coronary atherosclerosis may be a linkage marker for an atherogenic gene in the apo AI-CI11-AIV gene complex. Such a linkage marker is likely to vary among the races.
In the previous study, we revealed that the haplotypes identified by the apo CIII Sst-I and apo AI Msp-I polymorphisms are useful genetic markers for Japanese (Onuki et al., 1986) . In the present study, the haplotypes identified by the apo ClII Sst-I and apo AI Msp-[ polymorphisms were investigated in Japanese myocardial infarction survivors, as an attempt to find a linkage marker for the putative atherogenic gene in the apo AI-CIII-AIV gene complex in Japanese.
MATERIALS AND METHODS
Blood was collected from 69 Japanese myocardial infarction survivors without diabetes mellitus (59 males, 10 females) attending the cardiac clinics at Tsuchiurakyodo Hospital and Tsukuba Medical Center, Ibaraki-ken. Diagnosis was confirmed by clinical history, typical electrocardiographic changes and enzyme examination. The mean (_ SD) age of the myocardial infarction survivors was 59___ t0.
DNA was isolated from whole blood cells essentially according to the method of Kunkel et al. (1977) . The apo CllI Sst-I genotypes and apo AI Msp-I genotypes were analyzed by Southern blotting using azp-labeled human apo AI clone composing 2.2 kb Pst-I fragment of an apo A1 genomic clone as described previously (Southern, 1975; Kessling et al., 1985; Onuki et al., 1986) .
Association analysis between myocardial infarction and the haplotype identified by the apo AI-CIII Sst-I and Msp-I polymorphisms was performed in 2 x 2 tables by chi-square statistics. In the association analysis, the data on 82 unrelated healthy members of the university staffs and students (age range 20-62, mean age 30_ 12) were used as the control; the data was described in detail previously (Onuki et al., 1986 ).
RESULTS
Figure 1 shows simplified restriction site maps for the Sst-I and Msp-I polymorphisms in the apo AI-CIII genes. Table 1 presents the distribution and allele frequencies of the apo CII[ Sst-I genotypes and apo AI Msp-I genotypes in 69 myocardial infarction survivors and 82 unrelated healthy subjects. Both the frequencies of the $2 and M2 alleles were high in myocardial infarction survivors and healthy subjects, and no significant differences in the frequencies of the alleles were observed between the two groups.
In the previous study we clearly demonstrated that the alleles identified by the apo CIII Sst-I and apo Al Msp-I polymorphisms are in linkage disequilibrium (Onuki et al., 1986) . As observed in the previous study, none of 69 subjects examined in this study had the genotypes, SIS2MIM1, S2S2MIM1, and S2S2MIM2. Since the haplotype $2-M1 is considered to be absent, or, if present, very rare and negligible in Japanese, the combination of the haplotypes identified by these polymorphisms is easily determined for each individual when the genotypes of the polymorphisms are known. Table 2 shows the distribution of the combined haplotypes in myocardial infarction survivors and healthy subjects. The frequency of the individuals with the haplotype S1-M2 (that is genotypes S1SIM1M2, SIS2M2M2) is significantly increased in myocardial infarction survivors compared with healthy subjects (24.6}~ versus 11.0~, p<0.05). The frequency of each haplotype in myocardial infarction survivors and healthy subjects is shown in Fig. 1 ; the frequencies of the haplotype S1-M2 are 0.123 in myocardial infarction survivors and 0.055 in healthy subjects, and the difference is also significant (Z2=4.30, d.f. 1, p<0.05).
DISCUSSION
The $2 and M2 alleles, especially the $2 allele, have been reported to be relatively uncommon and associated with coronary atherosclerosis in some local Caucasians (Ferns et al., 1985; Rees et al., 1985; Ferns and Galton, 1986; Deeb et al., 1986; Acton et al., 1986) . In the case of Japanese, however, our data indicate that both the $2 and M2 alleles are common and not associated with coronary atherosclerosis. The apo CII1 Sst-I polymorphism arises from a C-G transversion in the 3'-non-coding region of the apo CIII gene (Karathanasis et al., 1983a) . The apo A1 Msp-I polymorphism arises from the presence or absence of a Msp-I site in the third intron of the apo AI gene (Seilhamer et al., 1984) . Therefore it is considered that the $2 and M2 alleles may represent a linkage marker for an atherogenic gene at least in some local Caucasians but not in Japanese.
The haplotypes identified by the apo CIII Sst-I and apo AI Msp-I polymorphisms are useful genetic markers for the analysis of apo AI-CIII-AIV gene complex in Japanese (Onuki et al., 1986) . The results of the present study suggest that the haplotype S1-M2 may be a linkage marker for the putative atherogenic gene in APO AI-Clll RFLPs AND MYOCARDIAL INFARCTION Japanese. Our data seem to be consistent with the finding reported by Rees et al. (1986) that the haplotype $1-M2 is associated with hypertriglyceridemia in Japanese (Rees et al., 1986) . However, since the difference in the frequency of the haplotype S1-M2 between myocardial infarction survivors and healthy subjects may reflect regional differences, it is required to perform further case-control studies to confirm the results of the present study.
